Asia Pacific Egg Donation Market size crossed USD 80 million in 2020 and is projected to observe around 49.6% growth rate between 2021 and 2027.
Increasing awareness regarding reproductive technologies in developing countries will propel the market growth. Rising trend of delayed pregnancy will influence the industry revenue. High infertility rate is attributed to growing unhealthy habits in society such as alcohol consumption, smoking habits in women will enhance expansion opportunities for the market. Thus, artificial means such as surrogacy and ART have gained momentous popularity and awareness.
Get more details on this report - Request Free Sample PDF
Rising incidence rate of infertility conditions in underdeveloped and developing countries in Asia Pacific will augment the egg donation market size. Growing tourism for fertility and healthcare expenditure in developing economies will offer expansion opportunities to key players in the region. Increasing availability of healthcare settings and expanding network of facilities and egg banks in region will fuel the market demand.
Fresh egg donor segment dominated more than 81% market share in 2020, owing to advances in technologies. Use of fresh eggs in recipient woman is owing to poor ovarian reserve, absence of ovary, poor oocyte quality, and embryo quality. Fresh eggs are also used to avoid genetic disorders, cancer, and several other diseases. The success rate is higher in fresh egg cycle as compared to frozen eggs. Also, donor is chosen from patient’s relations that will increase the chance of fertilization. Multiple embryo and oocytes available for procedure enhances the chances of successful outcome.
Hospitals segment revenue in the Asia Pacific egg donation market will reach USD 250 million by 2027. Patient preference for hospital settings attributed to availability of advanced sophisticated equipments and skilled healthcare professionals will boost the segment growth in developing countries. Furthermore, hospitals have greater accessibility and distribution of novel treatments and advanced treatment alternatives. Most of the gynecological testing and treatments are performed by specialist in hospital settings into numerous developing countries of Asia Pacific region. Improvement in healthcare settings across the developing countries of the region will drive service demand.
Few of the established industry players include Virtus Health, Chennai Fertility Center Flinders Reproductive Medicine Pty Ltd., Southend Fertility and IVF, Morpheus Life Sciences Pvt. Ltd., Monash IVF Group, and Bangkok IVF Center. These strategic players are continuously providing and improving their services for better outcome and are involved in collaborations to cater growing patient pool.